Non-Alcoholic Fatty Liver Disease is Not Associated with Vitamin D Deficiency in Essential Hypertension Authors
Original Research Article
First Online: 13 April 2013 Received: 07 November 2012 Accepted: 14 January 2013 DOI:
Cite this article as: Catena, C., Cosma, C., Camozzi, V. et al. High Blood Press Cardiovasc Prev (2013) 20: 33. doi:10.1007/s40292-013-0010-7 Abstract
An independent association between non-alcoholic fatty liver disease (NAFLD), a condition characterized by insulin-resistance, and low serum 25-hydroxyvitamin D [25(OH)D] levels has been reported. 25(OH)D concentrations are directly related with insulin sensitivity, whereas low [25(OH)D] predicts development of hypertension independent of glucose homeostasis alterations. We hypothesized that hypertensive patients with NAFLD have lower 25(OH)D than those without. Forty-four essential hypertensive (EH) patients with (n = 23) or without (n = 21) NAFLD were studied. No patient had diabetes mellitus, obesity, hyperlipidemia. The two hypertensive groups were compared with 24 healthy normotensive sex-, age-, body mass index (BMI)-matched subject, as controls. The two hypertensive groups had comparable age, sex, and blood pressure. BMI, glucose, insulin, homeostasis model assessment (HOMA) index and alanine aminotransferase were higher (P < 0.001 to <0.05) and plasma adiponectin was lower (P < 0.05) in EH patients with NAFLD than in those without NAFLD. Vitamin D deficiency, as defined by 25(OH)D levels <50 nmol/L, was similarly frequent in EH patients and controls (47.7 % vs. 45.8 %, P NS). Prevalence of hypovitaminosis D was not different in EH patients with and without NAFLD (37.5 % vs. 38.8 %, P NS). In patients with EH and no additional cardiometabolic risk factors NAFLD is not associated with vitamin D deficiency.
Keywords Essential hypertension NAFLD Vitamin D References
Angulo P. GI epidemiology: non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25:883–9.
Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:27–38.
Fallo F, Dalla Pozza A, Sonino N, Lupia M, Tona F, Federspil G, Ermani M, et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Disc. 2009;19:646–53.
Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341–50.
Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med. 2011;9:85.
Zúñiga S, Firrincieli D, Housset C, Chignard N. Vitamin D and the vitamin D receptor in liver pathophysiology. Clin Res Hepatol Gastroenterol. 2011;35:295–302.
Kitson MT, Roberts SK. D-Livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol. 2012;57:897–909.
Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011;364:248–54.
Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxyvitamin D is predictive of future glycemic status and insulin resistance: the Medical Research council Ely Prospective Study 1990–2000. Diabetes. 2008;57:2619–25.
Liu E, Meigs JB, Pittas AG, McKeown NM, Economos CD, Booth SL, et al. Plasma 25-hydroxyvitamin D is associated with markers of the insulin resistance phenotype in nondiabetic adults. J Nutr. 2009;139:329–34.
Pilz S, Tomaschitz A, Ritz E, Pleber TR. Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol. 2009;6:621–30.
Muldowney S, Kiely M. Vitamin D and cardiometabolic health: a review of the evidence. Nutr Res Rev. 2011;1:1–20.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germanò G, et al. ESH-ESC Task Force on the Management of Arterial Hypertension 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87.
Fallo F, Dalla Pozza A, Sonino N, Federspil G, Ermani M, Baroselli S, et al. Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients. J Hypertens. 2008;26:2191–7.
Fallo F, Catena C, Camozzi V, Luisetto G, Cosma C, Plebani M, et al. Low serum 25-hydroxyvitamin D levels are associated with left ventricular hypertrophy in essential hypertension. Nutr Metab Cardiovasc Dis. 2012;22:871–6.
Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and cell dysfunction. Am J Clin Nutr. 2004;79:820–5.
Katz K, Brar PC, Parekh N, Liu YH, Weitzman M. Suspected nonalcoholic fatty liver disease is not associated with vitamin D status in adolescents after adjustment for obesity. J Obes. 2010; Article ID 496829.
Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2007;17:517–24.
Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836–46.
Zhou QG, Hou FF, Guo ZJ, Liang M, Wang GB. Dihydroxyvitamin D improved the free fatty-acid-induced insulin resistance in cultured C2C12 cells. Diabetes Metab Res. 2004;24:459–64.
CrossRef Copyright information
© Springer International Publishing Switzerland 2013